- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
Gavi, the Vaccine Alliance, has secured 500,000 doses of the MVA-BX mpox vaccine (JYNNEOS), to enhance access for African countries affected by the recent mpox outbreak. This initiative is funded by Gavi’s newly established First Response Fund, developed in response to the COVID-19 pandemic and seeks to ensure rapid access to vaccines during health emergencies. The vaccines are expected to be delivered in 2024, building on the previous delivery of over a quarter of a million doses of vaccines to the Democratic Republic of Congo, which were donated by various nations and allocated as per the WHO’s Access and Allocation Mechanism.
In addition to the immediate provision of vaccines, Gavi is taking steps to prepare for effective vaccination campaigns by allocating funds to train healthcare workers and engage communities in affected regions. The organisation is also exploring longer-term strategies, such as establishing a stockpile of mpox vaccines for future outbreaks and developing sustainable vaccine manufacturing capabilities in Africa. These efforts are part of a broader commitment to improving vaccine access and ensuring that vulnerable populations receive timely and effective health interventions.
Additional data provided by
English
Japanese
